Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (2019 - 2026)

InMed Pharmaceuticals has reported Shares Outstanding over the past 5 years, most recently at $2.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 287.24% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 287.24%, while the annual FY2025 figure was $2.0 million, 349.01% up from the prior year.
  • Shares Outstanding for Q4 2025 was $2.8 million at InMed Pharmaceuticals, up from $2.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $2.8 million in Q4 2025 and troughed at $166370.0 in Q2 2023.
  • A 5-year average of $944737.2 and a median of $571354.0 in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: surged 155.52% in 2024 and later surged 349.01% in 2025.
  • Year by year, Shares Outstanding stood at $322028.0 in 2021, then surged by 77.42% to $571354.0 in 2022, then plummeted by 50.4% to $283399.0 in 2023, then surged by 155.52% to $724152.0 in 2024, then surged by 287.24% to $2.8 million in 2025.
  • Business Quant data shows Shares Outstanding for INM at $2.8 million in Q4 2025, $2.6 million in Q3 2025, and $2.0 million in Q2 2025.